HC Wainwright Reaffirms Buy Rating for Evolus (NASDAQ:EOLS)

Evolus (NASDAQ:EOLS)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $13.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 48.06% from the company’s current price.

EOLS has been the subject of a number of other research reports. Wall Street Zen upgraded Evolus from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. BTIG Research reissued a “buy” rating and issued a $13.00 target price on shares of Evolus in a research note on Wednesday, June 17th. Finally, Weiss Ratings raised Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $14.50.

Evolus Stock Up 4.6%

Shares of EOLS opened at $8.78 on Tuesday. The business’s 50 day moving average price is $6.86 and its 200-day moving average price is $5.80. Evolus has a 52 week low of $3.86 and a 52 week high of $8.82. The stock has a market cap of $579.92 million, a P/E ratio of -16.88 and a beta of 1.35.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Rhumbline Advisers grew its holdings in shares of Evolus by 2.0% during the second quarter. Rhumbline Advisers now owns 85,093 shares of the company’s stock valued at $784,000 after buying an additional 1,657 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Evolus by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company’s stock worth $400,000 after acquiring an additional 1,838 shares during the last quarter. Invesco Ltd. lifted its position in Evolus by 7.5% in the 2nd quarter. Invesco Ltd. now owns 34,283 shares of the company’s stock valued at $316,000 after acquiring an additional 2,383 shares in the last quarter. California State Teachers Retirement System boosted its stake in Evolus by 79.9% during the 2nd quarter. California State Teachers Retirement System now owns 5,455 shares of the company’s stock valued at $38,000 after purchasing an additional 2,423 shares during the last quarter. Finally, Larson Financial Group LLC boosted its stake in Evolus by 136.6% during the 4th quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock valued at $33,000 after purchasing an additional 2,837 shares during the last quarter. Institutional investors own 90.69% of the company’s stock.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.